glp-1
Glucagon-like peptide-1 (GLP-1) is an incretin hormone derived from the intestine that stimulates insulin secretion in a glucose-dependent manner while suppressing glucagon release. It acts on the brain to increase satiety, delays gastric emptying, and is primarily used to treat type 2 diabetes and obesity through GLP-1 receptor agonists.
Lab Notes — Research Studies
01 GLP-1-based therapies for diabetes, obesity and beyond
This review confirms GLP-1 therapies like semaglutide and tirzepatide are highly effective for glucose control and weight loss while reducing cardiovascular and renal mortality.
View Study ((PubMed))02 Hypoglycemic effect of C. butyricum-pMTL007-GLP-1 engineered probiotics on type 2 diabetes mellitus
Engineered probiotics designed to continuously deliver GLP-1 successfully lowered blood glucose, improved islet cell function, and restored gut microbiota in diabetic models.
View Study ((PubMed))03 GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss
GLP-1 receptor agonists can cause significant muscle loss as a side effect, but blocking myostatin and activin A can preserve muscle mass and optimize metabolic outcomes.
View Study ((PubMed))04 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease
Clinical guidelines now formally recommend GLP-1 receptor agonists for patients with chronic coronary disease and type 2 diabetes to reduce major adverse cardiovascular events.
View Study ((PubMed))05 The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective
GLP-1 RAs show potential in managing reproductive health disorders like PCOS by restoring menstrual frequency and improving metabolic health.
View Study ((PubMed))06 GLP-1 rescued gestational diabetes mellitus-induced suppression of fetal thalamus development
Animal models suggest GLP-1 may protect fetal neurological development, specifically correcting impaired thalamocortical axon growth caused by maternal diabetes.
View Study ((PubMed))Formula — Benefits & Dosage
⚗️ Effects
- Rapid Weight Loss: Highly effective for obesity management, particularly when combined with lifestyle interventions.
- Chronic Management: Shows high long-term success for reversing prediabetes and managing type 2 diabetes.
- Metabolic Health: Effectively improves dyslipidemia and markers of inflammation like IL-6 and TNF-alpha.
- PCOS Regulation: Emerging utility in restoring menstrual cycles and managing insulin resistance in adolescents with PCOS.
💉 Dosage & Administration
- Titration Schedule: Commonly started at a low 'induction' dose (e.g., 0.25mg) to minimize nausea, increasing every 4 weeks.
- Short-acting vs Long-acting: Short-acting analogs may be used to specifically target postprandial glucose, while long-acting versions (weekly) are preferred for weight loss.
- Engineered Probiotics: Novel delivery methods via C. butyricum or L. gasseri are being researched to bypass daily injections.
- Nutraceutical Induction: 200mg daily of Eriocitrin has been shown to naturally increase endogenous GLP-1 levels by 17%.
⚠️ Side Effects
- Gastrointestinal Distress: Nausea, vomiting, and constipation are the most frequently reported user side effects.
- Muscle Loss: Loss of muscle mass is a significant concern, often requiring high protein intake and resistance training to mitigate.
- Islet Cell Apoptosis: In diseased states, GLP-1 therapies help retard islet cell apoptosis, which is a positive secondary effect.
- Gallbladder Issues: Rapid weight loss associated with GLP-1 can increase the risk of gallbladder-related complications.
📦 Availability & Sourcing
- Prescription Requirement: GLP-1 receptor agonists (Semaglutide, Tirzepatide) are strictly prescription-only medications.
- Supply Shortages: Significant global demand has led to frequent sourcing challenges and intermittent availability for patients.
Reaction Log — User Experiences
Users report transformative weight loss and high effectiveness for glycemic control, though they frequently discuss managing gastrointestinal side effects and the risk of muscle mass reduction.
Synthesis — Related Compounds
⚠️ IMPORTANT DISCLAIMER
This information is for educational and research purposes only. glp-1 may not be approved for human use. Always consult a qualified healthcare professional before using any supplements or research compounds. We do not guarantee accuracy or completeness of information presented.